Family · Pharmaceutical analytical standards
Febuxostat
A xanthine oxidase inhibitor, blocking the enzyme that produces uric acid: discovered in Japan, it was approved in the US in 2009 for the long-term treatment of hyperuricaemia in people with gout. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?At its US debut it was presented as the first new treatment option in more than 40 years for gout-related hyperuricaemia.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
